U.S. FDA Gives Its Nod to Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for roflumilast topical foam 0.3% (Zoryve, Arcutis) for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.